> top > docs > PMC:7696151 > spans > 84214-86809 > annotations

PMC:7696151 / 84214-86809 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
2531 123-131 Species denotes patients Tax:9606
2532 479-486 Species denotes patient Tax:9606
2533 732-736 Species denotes mice Tax:10090
2534 967-975 Species denotes patients Tax:9606
2535 1279-1287 Species denotes patients Tax:9606
2536 1422-1430 Species denotes Patients Tax:9606
2537 1727-1735 Species denotes patients Tax:9606
2538 1854-1862 Species denotes patients Tax:9606
2539 2500-2508 Species denotes patients Tax:9606
2540 2580-2588 Species denotes patients Tax:9606
2541 30-33 Chemical denotes HCQ MESH:D006886
2542 147-159 Chemical denotes temozolomide MESH:D000077204
2543 401-404 Chemical denotes HCQ MESH:D006886
2544 624-627 Chemical denotes HCQ MESH:D006886
2545 759-762 Chemical denotes HCQ MESH:D006886
2546 862-865 Chemical denotes HCQ MESH:D006886
2547 1076-1088 Chemical denotes temsirolimus MESH:C401859
2548 1110-1113 Chemical denotes HCQ MESH:D006886
2549 1220-1223 Chemical denotes HCQ MESH:D006886
2550 1357-1369 Chemical denotes temozolomide MESH:D000077204
2551 1394-1397 Chemical denotes HCQ MESH:D006886
2552 1791-1794 Chemical denotes HCQ MESH:D006886
2553 1992-1995 Chemical denotes HCQ MESH:D006886
2554 2000-2010 Chemical denotes bortezomib MESH:D000069286
2555 2110-2113 Chemical denotes HCQ MESH:D006886
2556 2131-2141 Chemical denotes bortezomib MESH:D000069286
2557 2296-2299 Chemical denotes HCQ MESH:D006886
2558 2384-2394 Chemical denotes everolimus MESH:D000068338
2559 110-122 Disease denotes glioblastoma MESH:D005909
2560 279-284 Disease denotes tumor MESH:D009369
2561 349-357 Disease denotes toxicity MESH:D064420
2562 522-530 Disease denotes toxicity MESH:D064420
2563 542-558 Disease denotes myelosuppression MESH:D001855
2564 560-568 Disease denotes anorexia MESH:D000855
2565 570-577 Disease denotes fatigue MESH:D005221
2566 582-588 Disease denotes nausea MESH:D009325
2567 987-993 Disease denotes tumors MESH:D009369
2568 1008-1016 Disease denotes melanoma MESH:D008545
2569 1162-1167 Disease denotes tumor MESH:D009369
2570 1264-1272 Disease denotes toxicity MESH:D064420
2571 1304-1312 Disease denotes melanoma MESH:D008545
2572 1633-1643 Disease denotes toxicities MESH:D064420
2573 1741-1748 Disease denotes myeloma MESH:D009101
2574 2049-2056 Disease denotes myeloma MESH:D009101
2575 2247-2253 Disease denotes cancer MESH:D009369
2576 2336-2344 Disease denotes toxicity MESH:D064420
2577 2468-2499 Disease denotes clear-cell renal cell carcinoma MESH:C538614

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T205 110-122 Phenotype denotes glioblastoma http://purl.obolibrary.org/obo/HP_0012174
T206 279-284 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T207 560-568 Phenotype denotes anorexia http://purl.obolibrary.org/obo/HP_0002039
T208 570-577 Phenotype denotes fatigue http://purl.obolibrary.org/obo/HP_0012378
T209 582-588 Phenotype denotes nausea http://purl.obolibrary.org/obo/HP_0002018
T210 1008-1016 Phenotype denotes melanoma http://purl.obolibrary.org/obo/HP_0002861
T211 1162-1167 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T212 1304-1312 Phenotype denotes melanoma http://purl.obolibrary.org/obo/HP_0002861
T213 2224-2243 Phenotype denotes autophagic vacuoles http://purl.obolibrary.org/obo/HP_0003736
T214 2247-2253 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T215 2468-2499 Phenotype denotes clear-cell renal cell carcinoma http://purl.obolibrary.org/obo/HP_0006770

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T537 0-183 Sentence denotes The anticancer effect of free HCQ at 200–800 mg/day p.o. has been evaluated in two similar clinical trials on glioblastoma patients in concomitant temozolomide drugs and radiotherapy.
T538 184-415 Sentence denotes Although a dose-dependent significant increase of autophagy markers, no significant effects on tumor suppression were recorded in both studies, as the dose-limiting toxicity was not allowed to achieve higher doses of HCQ [162,165].
T539 416-589 Sentence denotes The maximum tolerated dose is the dose over which at least one patient from six experienced dose-limiting toxicity, including myelosuppression, anorexia, fatigue, or nausea.
T540 590-774 Sentence denotes Moreover, it has been proved that HCQ severely altered the organization of the Golgi apparatus and the endolysosomal system in C57BL/6JolaHsd mice under 60 mg/kg/day of HCQ i.p. [166].
T541 775-1027 Sentence denotes However, different from Rosenfeld’s studies, no maximum tolerated dose was reached for HCQ in combination with chemotherapic temsirolimus, allowing us to perform a dose-escalation study on 27 patients with solid tumors and 12 with a melanoma diagnosis.
T542 1028-1181 Sentence denotes In both cases, the standard intravenous dose of temsirolimus with 1200 mg of oral HCQ was considered safe and tolerated and inhibited tumor growth [167].
T543 1182-1421 Sentence denotes The same authors further assessed the HCQ anticancer properties and dose-limiting toxicity on 40 patients with metastatic melanoma, by administering a dose intense regimen of temozolomide and escalating doses of HCQ (200–1200 mg/day p.o.).
T544 1422-1577 Sentence denotes Patients well tolerated the treatment, showing a positive response in the 14% of cases and stability of disease in 27%, due to the modulation of autophagy.
T545 1578-1666 Sentence denotes No maximum tolerated dose was reached, although common toxicities were manifested [168].
T546 1667-1838 Sentence denotes According to the results of Rangwala, a phase I trial on 25 patients with myeloma demonstrated that the recommended dose of HCQ for a phase II trial is 600 mg twice a day.
T547 1839-2025 Sentence denotes Among eligible patients, 14% experienced a very good response, 14% minor responses, and 45% a period of stability in the disease when the association of HCQ and bortezomib were provided.
T548 2026-2266 Sentence denotes The synergic effect on myeloma was probably due to the combination of inhibition of HCQ on autophagy and bortezomib on proteasomal degradation, leading to the accumulation of misfolded proteins and autophagic vacuoles in cancer cells [169].
T549 2267-2595 Sentence denotes Likewise, doses of 600 mg of HCQ twice a day are not associated with toxicity and its usage as adjuvant therapy with everolimus was well tolerated and produced disease control in 67% of the metastatic clear-cell renal cell carcinoma patients and achieved the rate of six month progression-free survival in 45% of patients [170].